Sermorelin: evidence, FDA history and costs

Sermorelin was FDA-approved in two former Geref applications: a pituitary-function diagnostic and a treatment for children with growth failure. Both approvals were withdrawn in 2009 at the maker’s request ^[8]. FDA later determined that withdrawal was not for safety or effectiveness ^[7]. Current compounded telehealth products are not FDA-approved.

Sermorelin is a lab-made copy of the start of growth-hormone-releasing hormone

Your hypothalamus releases growth-hormone-releasing hormone (GHRH), which tells the pituitary gland to release growth hormone. Sermorelin is the first 29 amino acids of that signal, made in a lab. The Geref studies call it GHRH(1-29) ^[13].

That distinction matters. Sermorelin contains no growth hormone. It works upstream, so its effect depends on a pituitary that can still respond. In older men, it raised the body's own night-time growth-hormone release ^[14]. This is also why Geref's first approval was as a diagnostic test: doctors used it to check whether the pituitary could release growth hormone at all ^[7].

Geref was approved for a pituitary test and for children with growth failure

FDA approved Geref Diagnostic in 1990 to test whether the pituitary can release growth hormone (NDA 19-863). In 1997 it approved Geref to treat idiopathic growth-hormone deficiency in children with growth failure (NDA 20-443) ^[7]. Both conflicting dates you'll see online are right: they belong to two different applications.

The therapeutic approval covered children with growth failure; neither application approved adult wellness treatment for aging, energy, sleep or body composition. EMD Serono told FDA in 2008 that it was discontinuing both products and asked FDA to withdraw the applications, which FDA did in 2009 ^{[7] [8]}. FDA’s historical notice documents both withdrawals ^[7].

The 2013 determination permits FDA to approve generic applications if all other requirements are met; it does not itself approve a generic product ^[7]. The current FDA ingredient query returned the discontinued diagnostic application, and the reviewed DailyMed search did not identify a current sermorelin label. These search results are not an exhaustive proof about every database entry ^[9].

What it's prescribed for now: adult uses FDA never approved

Telehealth providers prescribe compounded sermorelin to adults for energy, body composition, sleep and healthy aging. None of those uses has ever been FDA-approved, and the small, short adult studies do not establish those broad benefits for current compounded products. The current product is compounded and is not FDA-approved. A prescription does not change that product status; its suitability and the legal requirements for the specific preparation need separate consideration.

The old approved product and today's compounded preparations require different questions. The former pediatric indication and current adult wellness marketing need separate evidence assessments. The selected adult studies below include both positive and negative outcomes. Whether the adult benefit is real is the subject of does sermorelin work.

The evidence: clear growth in children, small and mixed results in adults

An uncontrolled pediatric study reported increased growth velocity. An open-label study gave 110 untreated prepubertal children nightly injections for up to a year. Average height velocity rose from 1.6 inches (4.1 cm) a year to 3.1 inches (8.0 cm) a year at six months and 2.8 inches (7.2 cm) at twelve months ^[13]. Bone age did not outpace height, and 74% were rated good responders at six months. The study had no control group.

Adults are another matter. In 11 healthy men aged 64 to 76, six weeks of nightly self-injections raised night-time growth-hormone release. They did not change IGF-1, weight, body-mass index, or muscle and fat measured by DEXA ^[14]. Two of six strength measures improved. The authors themselves wrote that a single nightly dose was less effective than multiple daily doses.

Vittone’s once-nightly regimen raised GH without increasing IGF-I or changing DXA body composition ^[14]. Corpas used a different, twice-daily GHRH(1-29) protocol and did increase IGF-I over two weeks ^[6]. Koutkia’s small Geref trial found secondary body-composition changes in men with HIV lipodystrophy ^[2]. These findings cannot be reduced to a single universal response or transferred directly to general wellness use.

One other often-cited adult report used a related analog. It tested [Nle27]GHRH(1-29), an analog with one amino acid swapped, in 19 older men and women; growth hormone and IGF-1 rose and some immune markers shifted by 16 weeks of treatment ^[15]. It is close kin to sermorelin, not the same molecule.

Corpas and colleagues studied ten older men through two 14-day courses of GHRH(1-29), in randomized dose order, with nine younger men providing a baseline comparison. The higher regimen increased growth-hormone and IGF-I measures; fasting glucose, urinary C-peptide, blood pressure and routine chemistry were unchanged ^[6]. This is another adult exposure study, not proof of improved body composition, long-term safety or a schedule for current compounded products.

The broader GHRH sleep literature also prevents a blanket claim that sleep was never studied. Kern and colleagues found no sleep change during an overnight GHRH infusion experiment in ten men ^[3]. Perras and colleagues used intranasal GHRH in a crossover study of twelve younger and eleven older men and reported increases in REM and slow-wave sleep ^[4]. These acute, route-specific experiments do not establish the long-term benefits of commercially offered compounded sermorelin or a preferred injection timetable.

Safety: short studies reported it well tolerated, but there is no current label

The published studies reported sermorelin as well tolerated. In the children's study there were no adverse changes in routine blood chemistry or hormones, no change in fasting glucose and no excess rise in IGF-1 ^[13]. The six-week study in older men saw no significant adverse effects ^[14].

Those studies were small and short, and they are decades old. The absence of a current label does not imply an absence of risk. Small studies cannot reliably estimate uncommon adverse effects or drug interactions. The selected short studies do not establish long-term safety for current compounded products. We go through what is and isn't known in is sermorelin safe.

FDA history: approvals, withdrawal and compounding lists

Sermorelin's dates trip up a lot of pages. A date in 2008 means discontinuation, 2009 means FDA withdrew the approvals, and 2013 is FDA's determination that the withdrawal wasn't about safety. For the approval question on its own, see is sermorelin FDA approved.

Four sermorelin claims that don't match the record

Sermorelin's history makes it easy to describe loosely. These four lines show up on sales pages and in search results, and each one is wrong or overstated.

Sermorelin is sold as a compounded drug, which FDA does not review for quality

Sermorelin is not listed in the current 503A nomination categories ^[10]. The separate 503B document lists sermorelin acetate in Category 1, under evaluation, marked as a component of an approved drug ^[11]. A category listing is not approval of a compounded product.

FDA’s 503A framework allows a bulk substance route based on an applicable compendial monograph, an approved-drug component or the final bulks list, subject to the remaining statutory conditions. A historical ingredient status does not automatically establish that a particular preparation meets those conditions. Compounded drugs are not FDA-approved; the exact facility, prescription and product remain important ^[12].

Injection and oral preparations: evidence depends on the route

The former Geref products were injections ^[7]. Current selected provider pages offer injections and oral preparations ^{[19] [20]}. Older intranasal GHRH(1-29) studies also measured absorption and hormone responses; it would be wrong to say that nasal administration has never been tested ^{[17] [18]}. Those studies do not validate a current commercial tablet or nasal spray. See the oral and nasal evidence review.

Sermorelin vs related growth-hormone peptides

Sermorelin is often sold or compared alongside three other growth-hormone peptides. Their legal positions differ more than their chemistry.

The most common head-to-head question gets its own page: sermorelin vs ipamorelin.

Three things sermorelin is not, because sales pages blur them:

• Not growth hormone. It contains none; it asks the pituitary to make its own.
• Not an FDA-approved adult treatment. Adult wellness treatment was not an approved indication; the current compounded products are not FDA-approved.
• Not interchangeable with tesamorelin. Tesamorelin is a different molecule with approved formulations that do not qualify for the 503A/503B compounding exemptions.

What sermorelin costs from telehealth providers

These selected injection offers disclose different levels of billing detail. A monthly comparison figure does not change the amount or timing of the actual charge. The wider provider directory includes prices requiring a written quote.

How to get sermorelin: a prescription and a pharmacy you can name

Compounded sermorelin needs a prescription. Telehealth providers run an online intake, a clinician reviews it, and a pharmacy ships the product. Before you join, ask:

• Which pharmacy makes it, and is it a 503A pharmacy or a 503B outsourcing facility?
• Does the clinician check IGF-1 or other labs before starting and during treatment, and are they included in the price?
• Which form is prescribed, and what evidence supports that form?
• What does month two cost, and how do you cancel?

Answers to those questions are what the checks read in each provider's fine print. The sermorelin providers by grade list shows the results, and how we check explains the method.

Terms used on this page

• GHRH: growth-hormone-releasing hormone, the brain's signal telling the pituitary to release growth hormone.
• IGF-1: insulin-like growth factor 1, a hormone the body makes in response to growth hormone; often used as a blood marker of growth-hormone activity.
• NDA withdrawal: FDA's removal of a drug's approval, here at the maker's request after it stopped selling the drug.
• 503B outsourcing facility: a compounder registered with FDA that can make larger lots, not only individual prescriptions.
• Off-label: use of an FDA-approved drug for an unapproved purpose. This term does not make a currently compounded sermorelin product FDA-approved.